Entrada Therapeutics (TRDA) Share-based Compensation (2020 - 2026)

Entrada Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 6.74% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.3 million (changed 0.02% YoY), while the FY2025 annual figure was $19.6 million, up 9.46% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.7 million, up from $4.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $68.3 million in Q4 2023, with the low at -$7.0 million in Q4 2022.
• The 5-year median for Share-based Compensation is $4.6 million (2024), against an average of $7.1 million.
• Peak annual rise in Share-based Compensation reached 1113.32% in 2022, while the deepest fall reached 581.0% in 2022.
• Entrada Therapeutics' Share-based Compensation stood at -$7.0 million in 2022, then jumped by 1074.11% to $68.3 million in 2023, then slumped by 93.12% to $4.7 million in 2024, then slipped by 7.28% to $4.4 million in 2025, then climbed by 8.86% to $4.7 million in 2026.
• Business Quant data shows TRDA's Share-based Compensation at $4.7 million in Q1 2026, $4.4 million in Q4 2025, and $5.1 million in Q3 2025.